Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tempus AI, Inc. Class A Common Stock (TEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: TEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $82.5
1 Year Target Price $82.5
| 4 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.92% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.61B USD | Price to earnings Ratio 41.79 | 1Y Target Price 82.5 |
Price to earnings Ratio 41.79 | 1Y Target Price 82.5 | ||
Volume (30-day avg) 12 | Beta - | 52 Weeks Range 31.36 - 104.32 | Updated Date 11/2/2025 |
52 Weeks Range 31.36 - 104.32 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.15 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.98% | Operating Margin (TTM) -19% |
Management Effectiveness
Return on Assets (TTM) -11.51% | Return on Equity (TTM) -97.95% |
Valuation
Trailing PE 41.79 | Forward PE - | Enterprise Value 16075816928 | Price to Sales(TTM) 16.4 |
Enterprise Value 16075816928 | Price to Sales(TTM) 16.4 | ||
Enterprise Value to Revenue 16.89 | Enterprise Value to EBITDA - | Shares Outstanding 168683769 | Shares Floating 104742082 |
Shares Outstanding 168683769 | Shares Floating 104742082 | ||
Percent Insiders 41.83 | Percent Institutions 44.84 |
Upturn AI SWOT
Tempus AI, Inc. Class A Common Stock
Company Overview
History and Background
Tempus AI, Inc. was founded in 2015 and is focused on providing data and analytics to personalize healthcare through the use of artificial intelligence. The company aims to collect and analyze large amounts of molecular and clinical data to help physicians make informed decisions about patient care.
Core Business Areas
- Genomic Sequencing: Provides comprehensive genomic sequencing services to identify genetic mutations and biomarkers relevant to patient treatment.
- Clinical Data Aggregation: Aggregates clinical data from various sources, including electronic health records, imaging data, and pathology reports, to create a comprehensive patient profile.
- AI-Powered Analytics: Utilizes artificial intelligence and machine learning to analyze data and identify patterns that can inform treatment decisions and accelerate drug discovery.
- Precision Medicine Platform: Offerings include molecular profiling tests, data analytics, and clinical trial matching services.
Leadership and Structure
The leadership team is headed by Eric Lefkofsky (Founder & CEO). The organizational structure comprises teams focused on genomics, data science, engineering, and commercial operations.
Top Products and Market Share
Key Offerings
- Tempus xT: A comprehensive genomic sequencing test designed to identify clinically relevant biomarkers. Market share data is not publicly available. Competitors include Foundation Medicine (FMI), Caris Life Sciences, and Guardant Health (GH).
- Tempus xE: An RNA sequencing test to provide a more complete molecular profile. Market share data is not publicly available. Competitors include NanoString Technologies and Qiagen.
- Tempus nG: Liquid biopsy-based genomic sequencing assay. Market share data is not publicly available. Competitors include Guardant Health and Exact Sciences (EXAS).
- TIME Trial Program: This program helps patients find clinical trials. Revenues are growing, but specific financials not provided. Competing companies are clinical trial matching services such as Trialjectory and Antidote.
Market Dynamics
Industry Overview
The precision medicine market is experiencing significant growth due to advancements in genomic sequencing and AI. Increasing adoption of personalized treatment approaches and rising cancer incidence are driving market expansion.
Positioning
Tempus AI, Inc. Class A Common Stock is positioned as a leading provider of AI-powered precision medicine solutions. Its competitive advantage lies in its comprehensive data platform, advanced analytics capabilities, and partnerships with healthcare providers and pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for precision medicine is estimated to be in the tens of billions of dollars. Tempus AI, Inc. Class A Common Stock is positioned to capture a significant share of this market by leveraging its data platform and AI capabilities.
Upturn SWOT Analysis
Strengths
- Comprehensive data platform
- Advanced AI capabilities
- Strong partnerships with healthcare providers
- Experienced management team
- Focus on innovation
Weaknesses
- Limited profitability
- High R&D expenses
- Regulatory complexities
- Dependence on partnerships
- Relatively new public company (high volatility)
Opportunities
- Expanding into new therapeutic areas
- Developing new AI-powered tools
- Forging partnerships with pharmaceutical companies
- Growing adoption of precision medicine
- International expansion
Threats
- Competition from established players
- Regulatory changes
- Data privacy concerns
- Economic downturn
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- FMI
- GH
- EXAS
Competitive Landscape
Tempus AI, Inc. Class A Common Stock competes with established players in the precision medicine market. Its competitive advantage lies in its AI capabilities and comprehensive data platform, but it faces challenges from larger companies with established market positions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are still being established since the recent IPO.
Future Projections: Future growth projections are dependent on market adoption of precision medicine, new product development, and partnerships. Analyst estimates are still being formulated.
Recent Initiatives: Recent initiatives include expanding its data platform, developing new AI-powered tools, and forging partnerships with pharmaceutical companies.
Summary
Tempus AI is a relatively new public company seeking to utilize precision medicine in cancer treatment. The company has strong AI capabilities, a comprehensive data platform, and partnerships with healthcare providers. While the market has a large TAM, the company faces competition and needs to navigate regulatory complexities. The company also has limited profitability and high R&D expense.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-Party Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky J.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2400 | Website https://www.tempus.com |
Full time employees 2400 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaboration agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. and Whitehawk Therapeutics, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.